Catalog No.
DVV03607
Expression system
Mammalian Cells
Species reactivity
Zaire ebolavirus (ZEBOV)
Host species
Humanized
Isotype
IgG1, kappa
Clonality
Monoclonal
Target
Envelope glycoprotein, GP1,2, GP, Shed GP, GP1,2-delta, GP1, GP2, GP
Concentration
3.75 mg/ml
Endotoxin level
Please contact with the lab for this information.
Purity
>95% as determined by SDS-PAGE.
Purification
Protein A/G purified from cell culture supernatant.
Accession
Q05320
Applications
Research Grade Biosimilar
Form
Liquid
Storage buffer
0.01M PBS, pH 7.4.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
Alternative Names
Ansuvimab-zykl, EBV114/EBB114, mab114, VRC-EBOMAB092-00-AB, mab114, CAS: 2375952-29-5
Clone ID
Ansuvimab
Antibodies to watch in 2021, PMID: 33459118
Ansuvimab-zykl, PMID: 33787830
Ansuvimab: First Approval, PMID: 33751449
Ansuvimab, PMID: 33497159
Monoclonal Antibody Approved to Treat Ebola, PMID: 33755619
Proteo-Genomic Analysis Identifies Two Major Sites of Vulnerability on Ebolavirus Glycoprotein for Neutralizing Antibodies in Convalescent Human Plasma, PMID: 34335620
Effect of anti-Ebola virus monoclonal antibodies on endogenous antibody production in survivors of Ebola virus disease in the Democratic Republic of the Congo: an observational cohort study., PMID:38043556
Ebanga™: The most recent FDA-approved drug for treating Ebola., PMID:36969842
The prophylactic and therapeutic efficacy of the broadly active antiviral ribonucleoside N4-Hydroxycytidine (EIDD-1931) in a mouse model of lethal Ebola virus infection., PMID:36379378
Effects of therapies for Ebola virus disease: a systematic review and network meta-analysis., PMID:35803293
Antibody Use during an Outbreak of Ebola Virus Disease in the Democratic Republic of Congo, 2020., PMID:35320651
A systematic review of Ebola virus disease outbreaks and an analysis of the efficacy and safety of newer drugs approved for the treatment of Ebola virus disease by the US Food and Drug Administration from 2016 to 2020., PMID:35085865
Structural Biology Illuminates Molecular Determinants of Broad Ebolavirus Neutralization by Human Antibodies for Pan-Ebolavirus Therapeutic Development., PMID:35082794
Identification and Characterization of a Novel Single Domain Antibody Against Ebola Virus., PMID:34632543
Post-exposure prophylaxis following high-risk contact with Ebola virus, using immunotherapies with monoclonal antibodies, in the eastern Democratic Republic of the Congo: an emergency use program., PMID:34587535
Proteo-Genomic Analysis Identifies Two Major Sites of Vulnerability on Ebolavirus Glycoprotein for Neutralizing Antibodies in Convalescent Human Plasma., PMID:34335620
Ansuvimab-zykl., PMID:33787830
Monoclonal Antibody Approved to Treat Ebola., PMID:33755619
Ansuvimab: First Approval., PMID:33751449
Antibodies to watch in 2021., PMID:33459118
For research use only. Not for human or drug use.
